Differential requirements by CD4+ and CD8+ T cells for soluble and membrane TNF in control of Francisella tularensis live vaccine strain intramacrophage growth

Journal of Immunology

Volumn 179, Issue 11, 2007, Pages 7709-7719

  Cowley, Siobhán C ^a   Sedgwick, Jonathon D ^b   Elkins, Karen L ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 12P40; LIVE VACCINE; NITRIC OXIDE; NITRITE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; BACTERIAL VACCINE; INTERLEUKIN 12;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL GROWTH; CELL ISOLATION; CELL LINE; CELL STIMULATION; COCULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FRANCISELLA TULARENSIS; GROWTH REGULATION; IN VITRO STUDY; INFECTION SENSITIVITY; MACROPHAGE; MALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; TISSUE CULTURE; TRANSGENIC MOUSE; TULAREMIA; WILD TYPE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL DIFFERENTIATION; CELL MEMBRANE; IMMUNOLOGY; MICROBIOLOGY; MOUSE MUTANT; PHYSIOLOGY; SOLUBILITY;

ANIMALS; BACTERIAL VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL MEMBRANE; FRANCISELLA TULARENSIS; INTERFERON TYPE II; INTERLEUKIN-12; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NITRIC OXIDE; SOLUBILITY; TUMOR NECROSIS FACTORS;

EID: 38849113937     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.11.7709     Document Type: Article

References (46)

1. Tärnvik, A. 1989. Nature of protective immunity to Francisella tularensis. Rev. Infect. Dis. 11: 440-451.
2. Dennis, D. T., T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, A. M. Friedlander, J. Hauer, M. Layton, et al. 2001. Tularemia as a biological weapon: medical and public health management. J. Am. Med. Assoc. 285: 2763-2773.
3. Eigelsbach, H. T., and C. M. Downs. 1961. Prophylactic effectiveness of live and killed tularemia vaccines. J. Immunol. 87: 415-425.
4. Tärnvik, A., M. Eriksson, G. Sändstrom, and A. Sjöstedt. 1992. Francisella tularensis-a model for studies of the immune response to intracellular bacteria in man. Immunology 76: 349-354.
5. Fortier, A. H., T. Polsinelli, S. J. Green, and C. A. Nacy. 1992. Activation of macrophages for destruction of Francisella tularensis: identification of cytokines, effector cells, and effector molecules. Infect. Immun. 60: 817-825.
6. Elkins, K. L., R. K. Winegar, C. A. Nacy, and A. H. Fortier. 1992. Introduction of Francisella tularensis at skin sites induces resistance to infection and generation of protective immunity. Microb. Path. 13: 417-421.
7. Elkins, K. L., S. C. Cowley, and C. M. Bosio. 2003. Innate and adaptive immune responses to an intracellular bacterium Francisella tularensis live vaccine strain. Microbes Infect. 5: 132-142.
8. Sjöstedt, A., R. J. North, and J. W. Conlan. 1996. The requirement of tumour necrosis factor-α and interferon-γ for the expression of protective immunity to secondary murine tularaemia depends on the size of the challenge inoculum. Microbiology 142: 1369-1374.
9. Black, R. A., C. T. Rauch, C. J. Kozlosky, J. J. Peschon, J. L. Slack, M. F. Wolfson, B. J. Castner, K. L. Stocking, P. Reddy, S. Srinivasan, et al. 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 385: 729-733.
10. Decker, T., M. L. Lohmann-Matthes, and G. E. Gifford. 1987. Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J. Immunol. 138: 957-962.
11. Caron, G., Y. Delneste, J. P. Aubry, G. Magistrelli, N. Herbault, A. Blaecke, A. Meager, J. Y. Bonnefoy, and P. Jeannin. 1999. Human NK cells constitutively express membrane TNF-α (mTNFα) and present mTNFα-dependent cytotoxic activity. Eur. J. Immunol. 29: 3588-3595.
12. + T lymphocytes differ in their ability to activate macrophage antileishmanial defense. J. Leukocyte Biol. 51: 296-299.
13. + T lymphocyte plasma membrane. J. Exp. Med. 174: 755-759.
14. Ruuls, S. R., R. M. Hoek, V. N. Ngo, T. McNeil, L. A. Lucian, M. J. Janatpour, H. Korner, H. Scheerens, E. M. Hessel, J. G. Cyster, et al. 2001. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 15: 533-543.
15. Calabrese, L. 2006. The yin and yang of tumor necrosis factor inhibitors. Cleve. Clin. J. Med. 73: 251-256.
16. Rychly, D. J., and J. T. DiPiro. 2005. Infections associated with tumor necrosis factor-α antagonists. Pharmacotherapy 25: 1181-1192.
17. Mitoma, H., T. Horiuchi, N. Hatta, H. Tsukamoto, S. Harashima, Y. Kikuchi, J. Otsuka, S. Okamura, S. Fujita, and M. Harada. 2005. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α. Gastroenterology 128: 376-392.
18. Cowley, S. C., and K. L. Elkins. 2003. Multiple T cell subsets control Francisella tularensis LVS intracellular growth without stimulation through macrophage interferon γ receptors. J. Exp. Med. 198: 379-389.
19. Bosio, C. M., and K. L. Elkins. 2001. Susceptibility to secondary Francisella tularensis LVS infection in B cell deficient mice is associated with neutrophilia but not with defects in specific T cell mediated immunity. Infect. Immun. 69: 194-203.
20. + T cells mediate IFN-γ-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo. J. Immunol. 171: 4689-4699.
21. + T cells does not affect the magnitude of protective immunity to an intracellular pathogen. Francisella tularensis strain LVS. J. Immunol. 157: 5042-5048.
22. Fortier, A. H., M. V. Slayter, R. Ziemba, M. S. Meltzer, and C. A. Nacy. 1991. Live vaccine strain of Francisella tularensis: infection immunity in mice. Infect. Immun. 59: 2922-2928.
23. Anthony, L. S. D., P. J. Morrissey, and F. E. Nano. 1992. Growth inhibition of Francisella tularensis live vaccine strain by IFN-γ-activated macrophages is mediated by reactive nitrogen intermediates derived from L-arginine metabolism. J. Immunol. 148: 1829-1834.
24. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133-146.
25. Mueller, C., N. Corazza, S. Trachsel-Loseth, H. P. Eugster, M. Buhler-Jungo, T. Brunner, and M. A. Imboden. 1999. Noncleavable transmembrane mouse tumor necrosis factor-α (TNFα) mediates effects distinct from those of wild-type TNF α in vitro and in vivo. J. Biol. Chem. 274: 38112-38118.
26. Daubener, W., C. Remscheid, S. Nockemann, K. Pilz, S. Seghrouchni, C. Mackenzie, and U. Hadding. 1996. Anti-parasitic effector mechanisms in human brain tumor cells: role of interferon-γ and tumor necrosis factor-α. Eur. J. Immunol. 26: 487-492.
27. Robinson, C. M., K. A. Shirey, and J. M. Carlin. 2003. Synergistic transcriptional activation of indoleamine dioxygenase by IFN-γ and tumor necrosis factor-α. J. Interferon Cytokine Res. 23: 413-421.
28. Dellacasagrande, J., E. Ghigo, D. Raoult, C. Capo, and J. L. Mege. 2002. IFN-γ-induced apoptosis and microbicidal activity in monocytes harboring the intracellular bacterium Coxiella burnetii require membrane TNF and homotypic cell adherence. J. Immunol. 169: 6309-6315.
29. Musicki, K., H. Briscoe, S. Tran, W. J. Britton, and B. M. Saunders. 2006. Differential requirements for soluble and transmembrane tumor necrosis factor in the immunological control of primary and secondary Listeria monocytogenes infection. Infect. Immun. 74: 3180-3189.
30. Saunders, B. M., S. Tran, S. Ruuls, J. D. Sedgwick, H. Briscoe, and W. J. Britton. 2005. Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J. Immunol. 174: 4852-4859.
31. Saunders, B. M., H. Briscoe, and W. J. Britton. 2004. T cell-derived tumour necrosis factor is essential, but not sufficient, for protection against Mycobacterium tuberculosis infection. Clin. Exp. Immunol. 137: 279-287.
32. Olleros, M. L., R. Guler, D. Vesin, R. Parapanov, G. Marchal, E. Martinez-Soria, N. Corazza, J. C. Pache, C. Mueller, and I. Garcia. 2005. Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-Guérin and Mycobacterium tuberculosis infections. Am. J. Pathol. 166: 1109-1120.
33. Olleros, M. L., R. Guler, N. Corazza, D. Vesin, H. P. Eugster, G. Marchal, P. Chavarot, C. Mueller, and I. Garcia. 2002. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guérin infection in the absence of secreted TNF and lymphotoxin-α. J. Immunol. 168: 3394-3401.
34. Zganiacz, A., M. Santosuosso, J. Wang, T. Yang, L. Chen, M. Anzulovic, S. Alexander, B. Gicquel, Y. Wan, J. Bramson, et al. 2004. TNF-α is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J. Clin. Invest. 113: 401-413.
35. Mordue, D. G., F. Monroy, M. La Regina, C. A. Dinarello, and L. D. Sibley. 2001. Acute toxoplasmosis leads to lethal overproduction of Th1 cytokines. J. Immunol. 167: 4574-4584.
36. Mazzolini, G., J. Prieto, and I. Melero. 2003. Gene therapy of cancer with interleukin-12. Curr. Pharm. Des. 9: 1981-1991.
37. -/- mice is dependent on T cells and IL-12. J. Immunol. 165: 483-492.
38. Leenen, P. J., B. P. Canono, D. A. Drevets, J. S. Voerman, and P. A. Campbell. 1994. TNF-α and IFN-γ stimulate a macrophage precursor cell line to kill Listeria monocytogenes in a nitric oxide-independent manner. J. Immunol. 153: 5141-5147.
39. Liew, F. Y., Y. Li, and S. Millott. 1990. Tumor necrosis factor-α synergizes with IFN-γ in mediating killing of Leishmania major through the induction of nitric oxide. J. Immunol. 145: 4306-4310.
40. Flesch, I. E., J. H. Hess, I. P. Oswald, and S. H. Kaufmann. 1994. Growth inhibition of Mycobacterium bovis by IFN-γ stimulated macrophages: regulation by endogenous tumor necrosis factor-α and by IL-10. Int. Immunol. 6: 693-700.
41. Furst, D. E., R. Wallis, M. Broder, and D. O. Beenhouwer. 2006. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum. 36: 159-167.
42. Scallon, B., A. Cai, N. Solowski, A. Rosenberg, X. Y. Song, D. Shealy, and C. Wagner. 2002. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 301: 418-426.
43. Saliu, O. Y., C. Sofer, D. S. Stein, S. K. Schwander, and R. S. Wallis. 2006. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J. Infect. Dis. 194: 486-492.
44. Schaible, U. E., H. L. Collins, and S. H. Kaufmann. 1999. Confrontation between intracellular bacteria and the immune system. Adv. Immunol. 71: 267-377.
45. Manca, C., L. Tsenova, A. Bergtold, S. Freeman, M. Tovey, J. M. Musser, C. E. Barry, 3rd, V. H. Freedman, and G. Kaplan. 2001. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α/β. Proc. Natl. Acad. Sci. USA 98: 5752-5757.
46. Gerspach, J., A. Gotz, G. Zimmermann, C. Kolle, H. Bottinger, and M. Grell. 2000. Detection of membrane-bound tumor necrosis factor (TNF): an analysis of TNF-specific reagents. Microsc. Res. Tech. 50: 243-250.